DYNAMICS OF IL-6 AND CK-18 CONCENTRATION IN BLOOD PLASMA IN PATIENTS WITH FAMILIAL HYPERCHOLESTERINEMIA WITH NON-ALCOHOLIC STEATOHEPATITIS AGAINST THE BACKGROUND OF STATIN THERAPY AND HEPATOPROTECTOR (48-53)

Архив в PDF формате
Дата публикации статьи в журнале: 2019/09/19
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 48, Том: 3, Страницы в выпуске: 48-53
Автор: Maznichenko Iegor Aleksandrovich
, Odessa National Medical University ,
Анотация: There was made a comprehensive examination of 71 patients with FHC and NASH and formed groups of patients: I - n = 35 with FHC and NASH receiving rosuvastatin 20 mg / day; II - n = 36 of FHC and NASH who received rosuvastatin and hepatoprotector "Hepadif" 2 capsules three times a day for 90 days. The results were evaluated on the 45th and 90th day of treatment.
Ключевые слова: nonalcoholic steatohepatitis   familial hypercholesterolemia   hepatoprotector   interleukin-6   cytokeratin-18  
Данные для цитирования: Maznichenko Iegor Aleksandrovich , . DYNAMICS OF IL-6 AND CK-18 CONCENTRATION IN BLOOD PLASMA IN PATIENTS WITH FAMILIAL HYPERCHOLESTERINEMIA WITH NON-ALCOHOLIC STEATOHEPATITIS AGAINST THE BACKGROUND OF STATIN THERAPY AND HEPATOPROTECTOR (48-53). Восточно Европейский Научный Журнал. Медицинские науки. 2019/09/19; 48(3):48-53.

Список литературы: 1. Уніфікований клінічний протокол «Неалкогольний стеатогепатит». Наказ МОЗ України № 826 від 06.11.2014 року / М. К. Хобзей, Н. В. Харченко, О. М. Ліщина [та ін.] // 2014. [інтернет]. Доступно: http://mtd.dec.gov.ua/images/dodatki/2014_826Gepat yty/2014_826_YKPMD_NSTPT.pdf. 2. Маевская МВ, Морорзова МА. Возможности коррекции дислипидемии у пациентов с неалкогольной жировой болезнью печени. Гепатол. 2016;26(4):55-61. 3. Стаценко МЕ, Туркина СВ, Косивцова МА, Тыщенко ИА. Неалкогольная жировая болезнь печени, как мультисистемное заболевание. Вестник ВолгГМУ. 2016;2(58):8-14. 4. Bratoevka K, Nikolova S, Merdzhanova A, Stoyanov GS, Dimitrova E, Kashlov et al. Association between serum CK-18 levels and the degree of liver damage in fructose-inducted metabolic syndrome. Metab. Syndr. Relat Disord. Sep. 2018;16(7):350-7. 5. Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study / L. Klosiewicz-Latoszek, B. Cybulska, J. BialobreskaPaluszkiewicz et all // Arch. Med. Sci. 2018;14(5):962 - 970. 6. 2016 ESC/EAS Guidelines for the management of dyslipidemias / Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR) // Russ. J. Cardiol. 2017;5(145):P. 7 - 77. 7. Gidding SS, Champagne MA, Ferranti SD, Defesche J, Matthew K, Ito MK et al The agenda for Familial Hypercholesterolemia: a scientific statement from the American Heart Association. Circulation . Dec. 2015;132(22):2167 - 92p. doi:10.1161/CIR.000000000000029. 8. Hirsova P, Ibrahim SH, Gores GJ, Malhi M. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J. Lipid Res. 2016. Oct;57(10):1758-70 p. doi: 10.1194/jlr.R066357. 9. Kanda T, Matsuoka S, Yamazaki M, Shibata T, Nirei K, Takahashi H et al. Apoptosis and nonalcoholic fatty liver diseases.World J. Gastroenterol. 2018. Jul;24(25):2661-72 p. doi: 10.3748/wig.v24.i25.2661. 10. Kim EJ, Kim BH, Seo HS, Lee YJ, Kim HH, Son HH at al. Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PloS One. Jun. 2014;9(6):e97841. doi: 10.1371/journal.pone.0097841. eCollection 2014. 11. Knottnerus FJG, Bleeker JC, Wust RCI, Ferdinandusse S, IJist L, Wijburg FA et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev endocor Metab Diord.Mar 2018;19(1):93-106p. doi: 10.1007/s11154-018-9448-1. 12. Liang X, He Q, Zhao Q. Effect of statins on LDL Reduction and liver safety: a systematic review and meta-analysis. Biomed.Res Int.Mar 2018;5:7092414 doi:10.1155/2018/7092414 13. Mandelia C, Collyer E, Mansoor S, Lopez S, Lappe S, Nobili V et al. Plasma cytoceratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease. J Pediatr Nutr. Aug. 2016;63(12):181-7p. doi: 10.1097/MPG.0000000000001136. 14. Naseem S, Hussain T, Manzoor S. Interleukin-6: a promising cytokine to support liver regeneration and adaptive immunity in liver pathologies. Cytokine Growth factor Rev. Feb. 2018;39:36-45p. doi: 19.1016/j.cytogfr.2018.01.002 15. Sulivan EM, Pennington ER, Green WD, Beck MA, Brown DA, Shaikh SR. Mechanisms by which dietary fatty acids regulate mitochondrial structure-function in health and disease. Adv.Nutr. May. 2018;9(3):247-62p. doi: 10.1093/advances/nmy007 16. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. June.2016:64(6):1403-15p. doi:10.1016/j.hep.2016/02.004 17. Tajiri K, Futsukaichi Y, Kobayashi S, Yasumura S, Takahara T, Minemura M et al. Lcarnitine for the treatment of over hepatic encephalopathy in patients with advanced liver cirrhosis.J.Nutr. Sci. Vitaminol. 2018;64(5):321-28p. doi: 10.3177/jnsv.64.321. 18. Thota RN, Ferguson JJA, Abbott KA, Dias CB, Garg ML. Science behind the cardio-metabolic benefits of omega-3 polyunsaturated fatty acids: biochemical effects vs. clinical outcomes.Food Funct.Jul. 2018;9(7):3576-96p. doi: 10.1039/c8fo00348c. 19. Wang HH, Garruti G, Liu M, Porthincasa D, Wang DQ. Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport. Ann Hepatol. Nov. 2017:16(Suppl. 1: s3105.); s27-s.42p. doi:10.5604/01.3001.0010.5495. 20. WGO Global Guidelines NAFLD/NASH, (2012), 32 P.